Evvy Raised $40 Million for Microbiome Diagnostics
The New York-based company will use the funding to expand its metagenomic testing platform into fertility diagnostics.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you believe personalized diagnostic testing will improve the standard of care for women's health?
Evvy has secured $40 million in Series B funding, bringing its total equity raised to $60 million. The company provides a CLIA-certified metagenomic sequencing test that identifies over 700 bacteria and fungi via an at-home vaginal swab.
Why it matters
The company aims to address systemic gaps in women's health research by leveraging its proprietary vaginal microbiome dataset to develop new diagnostic models. The funding provides runway to validate these models as the firm expands access through health systems.
The platform identifies 700+ microbes, and a study of over 1,000 patients demonstrated a 50%+ reduction in bacterial vaginosis recurrence. These results are supported by 15+ peer-reviewed publications.
The players
Evvy
A New York-based health technology firm that builds metagenomic sequencing platforms for the vaginal microbiome.
Catalio Capital Management
A venture capital firm that focuses on biomedical and health technology companies and led this Series B round.
The details
Patients collect a vaginal swab at home, which the company processes using metagenomic sequencing—a method that sequences all genetic material in a sample to identify species without needing to culture them. Licensed clinicians then review the resulting molecular data and prescribe necessary treatments. This process builds on a growing dataset aimed at bridging historical data gaps in female health that persisted since clinical trials began requiring female participation in 1993.
Timeline
1993: Clinical trials began requiring female participants.
Next six months: Evvy plans to validate AI-powered diagnostic models.
The Tech Race
Evvy is working to translate its proprietary microbiome dataset into clinical diagnostics that address long-standing gaps in women's health data. This effort seeks to modernize standards for conditions that have historically lacked precision testing and targeted therapeutic protocols.
The platform currently serves over 100,000 patients and 3,000 practitioners who utilize the at-home swab process for clinical insights. Future updates are expected to expand these testing capabilities into fertility workflows and integrated health systems.
The takeaway
Evvy is prioritizing clinical validation of its diagnostic models over the next six months. Investors and patients should monitor the results of the company's upcoming prospective study in IVF clinics to track the firm's transition into the fertility market.
Further reading
For additional context on the evolving landscape of diagnostic technology, explore our latest reports in Biotech.
Source note: This article includes information reported by AlleyWatch.
Live Poll
Do you believe personalized diagnostic testing will improve the standard of care for women's health?
